Reports to: VP, US Medical Affairs & Patient Advocacy

About This Role:

The Sr. Director, Medical Affairs, Inherited Neurometabolic Disorders (IMD) is responsible for leading the U.S. Medical Affairs strategy for ITF Therapeutics' rare neurometabolic disease portfolio. Reporting to the Vice President of Medical Affairs & Patient Advocacy, this role serves as the senior U.S. medical leader for the neurometabolic therapeutics portfolio, ensuring effective translation of global medical strategy into impactful U.S. plans and successful launch execution.

As a member of the US Medical Affairs leadership team, the Senior Director provides strategic and scientific leadership across product development and commercialization, with responsibility for U.S. medical strategy, launch readiness, scientific engagement, field medical effectiveness, medical communications, education, payer engagement, and cross-functional execution.

Working closely with the Global Medical Director, this individual serves as the primary U.S. medical voice for the neurometabolic portfolio, ensuring global evidence generation, scientific communications, and medical activities address the needs of U.S. patients, healthcare professionals, payers, and other stakeholders.

The successful candidate will bring deep rare disease expertise, strong scientific and strategic leadership, and the ability to influence within a matrixed global organization. This leader will foster scientific excellence, collaboration, patient centricity, and innovation while helping establish ITF Therapeutics as a trusted partner within the neurometabolic community.

What You'll Do:

U.S. Medical Strategy & Leadership

Lead development and execution of integrated U.S. Medical Affairs strategies and tactical plans across pre-launch, launch, and lifecycle stages for the neurometabolic therapeutics portfolio.
Serve as the senior U.S. medical leader for target neurometabolic diseases, ensuring medical strategies support appropriate patient identification, disease knowledge, product knowledge, and improved patient outcomes.

Medical Launch Excellence

Lead all U.S. medical launch planning and execution activities related to the neurometabolic therapeutics portfolio.
Establish launch readiness plans spanning field medical, scientific communications, medical education, insight generation, congress strategy, advisory boards, and stakeholder engagement.
Partner with Commercial, Market Access, Regulatory, Patient Advocacy, Global Medical Affairs, and Clinical Development teams to ensure coordinated launch execution.
Identify and mitigate launch risks while addressing emerging opportunities and competitive dynamics.

Scientific Communications, Evidence Generation & Insights

Lead U.S. scientific communication and medical education strategies, including congress activities, scientific exchange, educational programs, and content development.
Ensure alignment of U.S. communication plans with global publication and evidence dissemination strategies.
Review and approve U.S. medical materials and ensure communications address stakeholder educational needs.
Drive insight generation processes and translate stakeholder insights into actionable recommendations that inform development, launch, and lifecycle strategies.
Provide U.S. strategic input into evidence generation priorities, study concepts, real-world evidence initiatives, publication planning, and data dissemination activities.
Monitor scientific, clinical, regulatory, policy, and competitive developments to inform decision-making.

External Engagement & Market Access

Build and maintain relationships with KOLs, investigators, healthcare professionals, patient advocacy organizations, professional societies, payers, and other stakeholders.
Lead advisory boards and expert consultation initiatives to inform medical strategy and evidence priorities.
Represent ITF Therapeutics at scientific, advocacy, and industry forums.
Partner with Market Access and HEOR to support generation and communication of evidence demonstrating clinical, economic, and patient-centered value.